Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04709276 · ClinicalTrials.gov registry record · Phase 2
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer
A Phase 2 study of Metastatic Prostate Cancer and Metastatic Prostate Neuroendocrine Carcinoma, sponsored by Andrew J. Armstrong, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 3
- Study locations
NCT04709276 is a Phase 2 study of Metastatic Prostate Cancer and Metastatic Prostate Neuroendocrine Carcinoma that is active but no longer recruiting, run by Andrew J. Armstrong, MD. The registered enrollment target is 41 participants, below the 186-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (78% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT04709276, a Phase 2 study of Metastatic Prostate Cancer and Metastatic Prostate Neuroendocrine Carcinoma, is active but no longer recruiting, sponsored by Andrew J. Armstrong, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of a combination of nivolumab, ipilimumab, cabazitaxel and carboplatin in men with neuroendocrine prostate cancer (NEPC) or other aggressive variants of prostate cancer (AVPC). This study will also investigate biomarkers to gain a better understanding of how the drug combination of nivolumab, ipilimumab, cabazitaxel and carboplatin affects these types of prostate cancer and the immune system. Eligible subjects will receive up to 10 cycles of nivolumab, ipilimumab, carboplatin and cabazitaxel followed by maintenance nivolumab and ipilimumab. Subjects may continue receiving study drugs until cancer progression, severe toxicity, withdrawal of consent, 3 years from the initial dose of study drugs or study termination, whichever occurs earlier. Subjects will be followed for 3 years from the initial dose of study drugs.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Cabazitaxel
Study Locations (3)
New York
- Weill Cornell Medicine - New York
North Carolina
- Duke University Medical Center - Durham
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2021-06-07 |
| Est. Completion | 2028-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04709276
The ClinicalTrials.gov registry entry for NCT04709276 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 186-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (78% lower). The listed sponsor is Andrew J. Armstrong, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT04709276 reports 3 study locations spanning 3 distinct geographic areas - top geographies include New York, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT04709276 about?
NCT04709276 is a clinical study titled "A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer". The purpose of this study is to evaluate the safety and efficacy of a combination of nivolumab, ipilimumab, cabazitaxel and carboplatin in men with neuroendocrine prostate cancer (NEPC) or other aggressive variants of prostate cancer (AVPC). This study will also investigate biomarkers to gain a bett...
What is the current status of trial NCT04709276?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2021-06-07. Estimated completion is 2028-08.
What conditions does trial NCT04709276 study?
This clinical trial studies the following conditions: Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma.
What interventions are being tested in trial NCT04709276?
The interventions under investigation include: Carboplatin (DRUG), Nivolumab (DRUG), Ipilimumab (DRUG), Cabazitaxel (DRUG).
Who is sponsoring clinical trial NCT04709276?
This trial is sponsored by Andrew J. Armstrong, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04709276 being conducted?
This trial has 3 study locations across New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
RECRUITING · Phase 2
-
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
RECRUITING · Phase 2
-
A Study of Tarlatamab for People With Prostate Cancer
RECRUITING · Phase 2
-
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
RECRUITING · Phase 2
-
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
RECRUITING · Phase 2
-
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
RECRUITING · Phase 2
Explore more on PlainTrial
Metastatic Prostate Cancer
All registered trials for this condition
Metastatic Prostate Neuroendocrine Carcinoma
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.